|
Welcome to the JN investor relations site. Innovation is our passion -- JN International Medical Corporation is a privately held "C" Corporation with market cap may reach up to $103 million during 2009-2011. We are one of the largest private manufactures and distributors of vaccines and diagnostics in Africa, South East Asia and Middle East. Explore this site to find more information about our breakthrough products and financial performance.
Assets and Stock information:
Investor Documents (download docs by pressing the arrow)
Nebraska Secretary of State: The assets of the corporation = $24.144 million in 2006-2007 
and
during 2009 the assets increased to $100 million (unaudited) based on
issued Patents, Sales and Assets of the corporation.
12,000 shares
were on Aug 2005 is
$9,250
/ share on private par
(Stock were issued from Founder to the shareholders and
Founder invested back into the company.
All
the discounted
share price had been adjusted according to number shares issued under
"C" corporation statue of the State of Nebraska.
Subsidiary company assets not included). - increase in share value
occurred due to issue of meningitis patent and consistence sale revenues
2007,2008 and 2009.
RETURN ON INVESTMENT (ROI)
Return on Investment on Meningitis A/C/Y/W-135 Vaccine alone: (Third World sales)
The following table shows the return on investment (ROI) for a 3-year period. The return on investment is based on the cash flows generated through normal operations. The return on investment does not include public offerings or other cash flows generated through possible sale of the company. The average return on investment is 46%, 39% and 53% respectively for 2009, 2010, and 2011 or average of 46% per year.
|
Investment |
3-year return |
3-year ROI |
|
$1,000,000 |
$460,000 |
46% |
|
$5,000,000 |
$2,300,000 |
46% |
|
|
|
|
Note: The ROI in the above table are estimates based on projected net income. These values will change as actual net income is recorded.
EXIT STRATEGY
It is our intent to become a buy-out target in the industry by focusing our competitors’ eyes on our advances. We will give the investor option to sellback his/her shares at 130% value of the original investment after 36 months if they choose to. This number can be recalculated if a potential investor deems it necessary to complete his/her investment into the company.
Disclaimer
Please read disclaimer before investing with our
corporation